[1]
|
International Agency for Research on Cancer, WHO (2020) Estimated Number of New Cases in 2020, Worldwide, Both Sexes, All Ages. https://gco.iarc.fr/
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[3]
|
Kopetz, S., Chang, G.J., Overman, M.J., Eng, C., Sargent, D.J., Larson, D.W., Grothey, A., Vauthey, J.N., Nagorney, D.M. and McWilliams, R.R. (2009) Improved Survival in Metastatic Col-orectal Cancer Is Associated with Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical On-cology, 27, 3677-3683.
https://doi.org/10.1200/JCO.2008.20.5278
|
[4]
|
中华医学会外科分会胃肠外科学组, 中华医学会外科分会结直肠外科学组, 中国抗癌协会大肠癌专业委员会, 等. 结直肠癌肝转移诊断和综合治疗指南(V2018) [J]. 中华结直肠疾病电子杂志, 2018, 7(4): 302-314.
|
[5]
|
De Ridder, J.A.M., Van Der Stok, E.P., Mekenkamp, L.J., et al. (2016) Management of Liver Metastases in Colorectal Cancer Patients: A Retrospective Case-Control Study of Systemic Thera-py versus Liver Resection. European Journal of Cancer, 59, 13-21. https://doi.org/10.1016/j.ejca.2016.02.003
|
[6]
|
Lai, H.W., Wei, J.C.C., Hung, H.C., et al. (2019) Impact of Treat-ment Modality on Clinical Outcome in Metastatic Colorectal Cancer Patients Stratified by Metastatic Sites. Postgraduate Medicine, 131, 163-170.
https://doi.org/10.1080/00325481.2019.1568016
|
[7]
|
Gill, S., Liu, D.M., Green, H.M., et al. (2018) Beyond the Knife: The Evolving Nonsurgical Management of Oligometastatic Colorectal Cancer. American Society of Clinical On-cology Educational Book, 38, 209-219.
https://doi.org/10.1200/EDBK_200941
|
[8]
|
Isoniemi, H. and Österlund, P. (2011) Surgery Combined with Onco-logical Treatments in Liver Metastases from Colorectal Cancer. Scandinavian Journal of Surgery, 100, 35-41. https://doi.org/10.1177/145749691110000107
|
[9]
|
Fiorentini, G., Sarti, D., Aliberti, C., et al. (2017) Multidisci-plinary Approach of Colorectal Cancer Liver Metastases. World Journal of Clinical Oncology, 8, 190-202. https://doi.org/10.5306/wjco.v8.i3.190
|
[10]
|
Tran, N.H., Cavalcante, L.L., Lubner, S.J., et al. (2015) Precision Medicine in Colorectal Cancer: The Molecular Profile Alters Treatment Strategies. Therapeutic Advances in Medical On-cology, 7, 252-262.
https://doi.org/10.1177/1758834015591952
|
[11]
|
Chow, F.C.L. and Chok, K.S.H. (2019) Colorectal Liver Metas-tases: An Update on Multidisciplinary Approach. World Journal of Hepatology, 11, 150-172. https://doi.org/10.4254/wjh.v11.i2.150
|
[12]
|
Chua, T.C., Saxena, A., Liauw, W., et al. (2010) Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases. Annals of Surgical Oncology, 17, 492-501. https://doi.org/10.1245/s10434-009-0781-1
|
[13]
|
Abdel-Rahman, O. and Cheung, W.Y. (2018) Integrating Sys-temic Therapies into the Multimodality Treatment of Resectable Colorectal Liver Metastases. Gastroenterology Research and Practice, 2018, Article ID: 4326082.
https://doi.org/10.1155/2018/4326082
|
[14]
|
Hackl, C., Loss, M., Klinkhammer-Schalke, M., et al. (2014) Treatment of Colorectal Liver Metastases in Germany: A Ten-Year Population-Based Analysis of 5772 Cases of Primary Colorectal Adenocarcinoma. BMC Cancer, 14, Article No. 810. https://doi.org/10.1186/1471-2407-14-810
|
[15]
|
Wang, Y., Wang, Z.Q., Wang, F.H., et al. (2017) The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile? Journal of Cancer, 8, 1179-1186.
https://doi.org/10.7150/jca.18091
|
[16]
|
Ciliberto, D., Prati, U., Roveda, L., et al. (2012) Role of Systemic Chemo-therapy in the Management of Resected or Resectable Colorectal Liver Metastases: A Systematic Review and Me-ta-Analysis of Randomized Controlled Trials. Oncology Reports, 27, 1849-1856.
|
[17]
|
Khoo, E., O’Neill, S., Brown, E., et al. (2016) Systematic Review of Systemic Adjuvant, Neoadjuvant and Perioperative Chemotherapy for Resectable Colorectal-Liver Metastases. HPB, 18, 485-493.
https://doi.org/10.1016/j.hpb.2016.03.001
|
[18]
|
Van Cutsem, E., Cervantes, A., Adam, R., et al. (2016) ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer. Annals of Oncology, 27, 1386-1422. https://doi.org/10.1093/annonc/mdw235
|
[19]
|
National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology—Antiemesis. National Comprehensive Cancer Network, 1, 1-43.
|
[20]
|
Goel, S., Wong, A.H. and Jain, R.K. (2012) Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease. Cold Spring Harbor Perspectives in Medicine, 2, a006486.
https://doi.org/10.1101/cshperspect.a006486
|
[21]
|
Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. https://doi.org/10.1007/s11523-017-0518-1
|
[22]
|
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. The New England Journal of Medicine, 350, 2335-2342. https://doi.org/10.1056/NEJMoa032691
|
[23]
|
Gordon, C.R., Rojavin, Y., Patel, M., Zins, J.E., Grana, G., Kann, B., Simons, R. and Atabek, U. (2009) A Review on Bevacizumab and Surgical Wound Healing: An Important Warning to All Surgeons. Annals of Plastic Surgery, 62, 707-709. https://doi.org/10.1097/SAP.0b013e3181828141
|
[24]
|
Scappaticci, F.A., Fehrenbacher, L., Cartwright, T., Hains-worth, J.D., Heim, W., Berlin, J., Kabbinavar, F., Novotny, W., Sarkar, S. and Hurwitz, H. (2005) Surgical Wound Healing Complications in Metastatic Colorectal Cancer Patients Treated with Bevacizumab. Journal of Surgical Oncology, 91, 173-180. https://doi.org/10.1002/jso.20301
|
[25]
|
Stewart, M.W. and Rosenfeld, P.J. (2008) Predicted Biological Activity of Intravitreal VEGF Trap. British Journal of Ophthalmology, 92, 667-668. https://doi.org/10.1136/bjo.2007.134874
|
[26]
|
Ciombor, K.K. and Berlin, J. (2014) Aflibercept—A Decoy VEGF Receptor. Current Oncology Reports, 16, 368.
https://doi.org/10.1007/s11912-013-0368-7
|
[27]
|
Tang, P.A., Cohen, S.J., Kollmannsberger, C., Bjarnason, G., Vi-rik, K., MacKenzie, M.J., Lourenco, L., Wang, L., Chen, A. and Moore, M.J. (2012) Phase II Clinical and Pharmacoki-netic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research, 18, 6023-6031.
https://doi.org/10.1158/1078-0432.CCR-11-3252
|
[28]
|
Folprecht, G., Pericay, C., Saunders, M.P., Thomas, A., Lopez, R., Roh, J.K., Chistyakov, V., Höhler, T., Kim, J.S., Hofheinz, R.D., et al. (2016) Oxaliplatin and 5-FU/Folinic Acid (Modified FOLFOX6) with or without Aflibercept in First-Line Treatment of Patients with Metastatic Colorectal Cancer: The AFFIRM Study. Annals of Oncology, 27, 1273-1279. https://doi.org/10.1093/annonc/mdw176
|
[29]
|
Tabernero, J., Yoshino, T., Cohn, A.L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.E., Portnoy, D.C., Van Cutsem, E., Grothey, A., et al. (2015) Ramucirumab ver-sus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Pro-gressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Random-ised, Double-Blind, Multicentre, Phase 3 Study. The Lancet Oncology, 16, 499-508. https://doi.org/10.1016/S1470-2045(15)70127-0
|
[30]
|
Modest, D.P., Pant, S. and Sartore-Bianchi, A. (2019) Treatment Sequencing in Metastatic Colorectal Cancer. European Journal of Cancer, 109, 70-83. https://doi.org/10.1016/j.ejca.2018.12.019
|
[31]
|
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. The New England Journal of Medicine, 351, 337-345. https://doi.org/10.1056/NEJMoa033025
|
[32]
|
Van Cutsem, E., Köhne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A., D’Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. The New England Journal of Medicine, 360, 1408-1417. https://doi.org/10.1056/NEJMoa0805019
|
[33]
|
Jonker, D.J., O’Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.J., Berry, S.R., Krahn, M., Price, T., Simes, R.J., et al. (2007) Cetuximab for the Treatment of Colorectal Cancer. The New England Journal of Medicine, 357, 2040-2048. https://doi.org/10.1056/NEJMoa071834
|
[34]
|
Heinemann, V., von Weikersthal, L.F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 15, 1065-1075. https://doi.org/10.1016/S1470-2045(14)70330-4
|
[35]
|
Addeo, R., Caraglia, M., Cerbone, D., Frega, N., Cimmino, G., Abbruzzese, A. and Del Prete, S. (2010) Panitumumab: A New Frontier of Target Therapy for the Treatment of Met-astatic Colorectal Cancer. Expert Review of Anticancer Therapy, 10, 499-505. https://doi.org/10.1586/era.10.28
|
[36]
|
Douillard, J.Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer. Annals of Oncology, 25, 1346-1355.
https://doi.org/10.1093/annonc/mdu141
|
[37]
|
Yoshino, T., Watanabe, J., Shitara, K., Yasui, H., Ohori, H., Shioza-wa, M., Yamazaki, K., Oki, E., Sato, T., Naitoh, T., et al. (2022) Panitumumab (PAN) plus mFOLFOX6 versus Bevacizumab (BEV) plus mFOLFOX6 as First-Line Treatment in Patients with RAS Wild-Type (WT) Metastatic Colo-rectal Cancer (mCRC): Results from the Phase 3 PARADIGM Trial. Journal of Clinical Oncology, 40, LBA1. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1
|
[38]
|
Ai, L., Chen, J., Yan, H., He, Q., Luo, P., Xu, Z. and Yang, X. (2020) Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Design, Develop-ment and Therapy, 14, 3625-3649.
https://doi.org/10.2147/DDDT.S267433
|
[39]
|
André, T., Shiu, K.K., Kim, T.W., Jensen, B.V., Jensen, L.H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) Pembrolizumab in Microsatel-lite-Instability-High Advanced Colorectal Cancer. The New England Journal of Medicine, 383, 2207-2218. https://doi.org/10.1056/NEJMoa2017699
|
[40]
|
Overman, M.J., McDermott, R., Leach, J.L., Lonardi, S., Lenz, H.J., Morse, M.A., Desai, J., Hill, A., Axelson, M., Moss, R.A., et al. (2017) Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Mul-ticentre, Phase 2 Study. The Lancet Oncology, 18, 1182-1191. https://doi.org/10.1016/S1470-2045(17)30422-9
|
[41]
|
Lenz, H.J., Van Cutsem, E., Luisa Limon, M., Wong, K.Y.M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D.B., et al. (2022) First-Line Nivolumab plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colo-rectal Cancer: The Phase II CheckMate 142 Study. Journal of Clinical Oncology, 40, 161-170. https://doi.org/10.1200/JCO.21.01015
|
[42]
|
Catenacci, D.V.T., Tebbutt, N.C., Davidenko, I., Murad, A.M., Al-Batran, S.E., Ilson, D.H., Tjulandin, S., Gotovkin, E., Karaszewska, B., Bondarenko, I., et al. (2017) Rilotumumab plus Epirubicin, Cisplatin, and Capecitabine as First-Line Therapy in Advanced MET-Positive Gastric or Gas-tro-Oesophageal Junction Cancer (RILOMET-1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 18, 1467-1482.
https://doi.org/10.1016/S1470-2045(17)30566-1
|
[43]
|
Doi, T., Kang, Y.-K., Muro, K., Jiang, Y., Jain, R.K. and Li-zambri, R. (2015) A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Rilotumumab in Combination with Cisplatin and Capecitabine (CX) as First-Line Therapy for Asian Patients (pts) with Advanced MET-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma: The RILOMET-2 Trial. Journal of Clin-ical Oncology, 33, TPS226.
https://doi.org/10.1200/jco.2015.33.3_suppl.tps226
|
[44]
|
Iveson, T., Donehower, R.C., Davidenko, I., Tjulandin, S., Deptala, A., Harrison, M., Nirni, S., Lakshmaiah, K., Thomas, A.., Jiang, Y., et al. (2014) Rilotumumab in Combination with Epirubicin, Cisplatin, and Capecitabine as First-Line Treatment for Gastric or Oesophagogastric Junction Adenocar-cinoma: An Open-Label, Dose De-Escalation Phase 1b Study and a Double-Blind, Randomised Phase 2 Study. The Lancet Oncology, 15, 1007-1018.
https://doi.org/10.1016/S1470-2045(14)70023-3
|
[45]
|
Van Cutsem, E.., Eng, C., Nowara, E., Swieboda-Sadlej, A., Tebbutt, N.C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., et al. (2014) Randomized Phase Ib/II Tri-al of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-Type KRAS Metastatic Colorectal Cancer. Clinical Cancer Research, 20, 4240-4250. https://doi.org/10.1158/1078-0432.CCR-13-2752
|
[46]
|
Shah, M.A., Bang, Y.J., Lordick, F., Alsina, M., Chen, M., Hack, S.P., Bruey, J.M., Smith, D., McCaffery, I., Shames, D.S., et al. (2017) Effect of Fluorouracil, Leucovorin, and Oxaliplatin with or without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. JAMA Oncology, 3, 620-627. https://doi.org/10.1001/jamaoncol.2016.5580
|
[47]
|
Bendell, J.C., Hochster, H., Hart, L.L., Firdaus, I., Mace, J.R., McFarlane, J.J., Kozloff, M., Catenacci, D., Hsu, J.J., Hack, S.P., et al. (2017) A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist, 22, 264-271.
https://doi.org/10.1634/theoncologist.2016-0223
|
[48]
|
Ciardiello, D., Vitiello, P.P., Cardone, C., Martini, G., Troiani, T., Martinelli, E. and Ciardiello, F. (2019) Immunotherapy of Colorectal Cancer: Challenges for Therapeutic Ef-ficacy. Cancer Treatment Reviews, 76, 22-32.
https://doi.org/10.1016/j.ctrv.2019.04.003
|
[49]
|
Diaz, L.A. and Le, D.T. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 373, 1979. https://doi.org/10.1056/NEJMc1510353
|
[50]
|
张文俊, 胡芳娟, 梁文波. 不可切除结直肠癌肝转移的射频消融治疗[J]. 中华肿瘤防治杂志, 2010, 17(24): 2075-2078. https://doi.org/10.16073/j.cnki.cjcpt.2010.24.021
|
[51]
|
王崑, 邢宝才. 结直肠癌肝转移的转化治疗[J]. 中国实用外科杂志, 2016, 36(4): 407-411.
|
[52]
|
Tago, T., Katsumata, K., Udou, R., Kasahara, K., Mazaki, J., Kuwabara, H., et al. (2021) Significance of Radiofrequency Ablation for Unre-sectable Colorectal Cancer with Liver Metastases. Anticancer Research, 41, 5539-5547.
https://doi.org/10.21873/anticanres.15367
|
[53]
|
Allard, M.A., Sebagh, M., Baillie, G., Lemoine, A., Dartigues, P., Faitot, F., Faron, M., Boige, V., Vitadello, F., Vibert, E., Elias, D., Adam, R., Goéré, D. and Sa Cunha, A. (2015) Com-parison of Complete Pathologic Response and Hepatic Injuries between Hepatic Arterial Infusion and Systemic Admin-istration of Oxaliplatin in Patients with Colorectal Liver Metastases. Annals of Surgical Oncology, 22, 1925-1932. https://doi.org/10.1245/s10434-014-4272-7
|
[54]
|
Jones, R.P., Hamann, S., Malik, H.Z., Fenwick, S.W., Poston, G.J. and Folprecht, G. (2014) Defined Criteria for Resectability Improves Rates of Secondary Resection after Systemic Therapy for Liver Limited Metastatic Colorectal Cancer. European Journal of Cancer, 50, 1590-1601. https://doi.org/10.1016/j.ejca.2014.02.024
|
[55]
|
Kelly, R.J., Kemeny, N.E. and Leonard, G.D. (2005) Current Strat-egies Using Hepatic Arterial Infusion Chemotherapy for the Treatment of Colorectal Cancer. Clinical Colorectal Cancer, 5, 166-174.
https://doi.org/10.3816/CCC.2005.n.027
|
[56]
|
Passot, G., Soubrane, O., Giuliante, F., Zimmitti, G., Goéré, D., Yamashita, S. and Vauthey, J.N. (2016) Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases. Liver Cancer, 6, 72-79.
https://doi.org/10.1159/000449349
|
[57]
|
Dueland, S., Guren, T.K., Hagness, M., Glimelius, B., Line, P.D., Pfeiffer, P., Foss, A. and Tveit, K.M. (2015) Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases from Colorectal Cancer? Annals of Surgery, 261, 956-960. https://doi.org/10.1097/SLA.0000000000000786
|
[58]
|
Hagness, M., Foss, A., Egge, T.S. and Dueland, S. (2014) Patterns of Recurrence after Liver Transplantation for Nonresectable Liver Metastases from Colorectal Cancer. Annals of Surgical Oncology, 21, 1323-1329.
https://doi.org/10.1245/s10434-013-3449-9
|
[59]
|
Toso, C., Pinto Marques, H., Andres, A., Castro Sousa, F., Adam, R., Kalil, A., Clavien, P.A., Furtado, E., Barroso, E., Bismuth, H. and Compagnons Hépato-Biliaires Group (2017) Liver Transplantation for Colorectal Liver Metastasis: Survival without Recurrence Can Be Achieved. Liver Transplantation, 23, 1073-1076. https://doi.org/10.1002/lt.24791
|